NCT00514085 2023-08-04
Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma
Canadian Cancer Trials Group
Phase 2 Completed
Clinical Trials
4 trialsNCT00667017 2018-12-14
RFT5-dgA Immunotoxin in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT01316692 2016-05-30
Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT00602199 2011-05-16
ABT-510 in Treating Patients With Metastatic Melanoma
Mayo Clinic
Phase 2 Completed